Related Experiment Video
Updated: Aug 17, 2026
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
Counting costs. Patients will suffer from limits on Alzheimer's drugs
1Manchester Memory Clinic, Wythenshawe Hospital.
Nursing Standard (Royal College of Nursing (Great Britain) : 1987)
|June 9, 2005
Insights
Draft guidelines suggest halting Alzheimer's disease drug prescriptions on the National Health Service (NHS). This potential policy change risks undermining proactive dementia care efforts and patient treatment strategies.
Area of Science:
- Neurology
- Geriatrics
- Pharmacology
Background:
- National Institute for Health and Clinical Excellence (NICE) is considering new guidelines.
- Current guidelines allow for Alzheimer's disease (AD) drug prescription on the NHS.
- Proactive dementia care is crucial for patient well-being.
Purpose of the Study:
- To analyze the potential impact of proposed NICE guidelines on Alzheimer's disease treatment.
- To evaluate the consequences of removing NHS prescription access for AD medications.
- To highlight the importance of continued proactive dementia care.
Main Methods:
- Review of draft NICE guidelines.
- Analysis of current NHS drug prescribing policies for AD.
- Assessment of the role of proactive care in dementia management.
Main Results:
- Proposed NICE guidelines recommend against prescribing AD drugs on the NHS.
- Implementation of these guidelines could lead to the cessation of current treatment protocols.
- Significant disruption to proactive dementia care services is anticipated.
Conclusions:
- The proposed NICE guidelines pose a threat to established Alzheimer's disease treatment.
- Discontinuation of NHS drug prescriptions may negatively impact dementia care.
- Urgent consideration is needed to preserve proactive dementia care services.
Abstract:
Draft guidelines from the National Institute for Health and Clinical Excellence (NICE), currently out for consultation, have suggested that drugs for the treatment of Alzheimer's disease should not be prescribed on the NHS. If this becomes policy, much of the proactive work in dementia care could be lost.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications